ERS Genomics with new CEO
Dublin-based ERS Genomics Ltd appointed John E Milad as CEO in the middle of May. He took over from Erik Rhodes, CEO for the last eight years.
ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 189 entries already.
Dublin-based ERS Genomics Ltd appointed John E Milad as CEO in the middle of May. He took over from Erik Rhodes, CEO for the last eight years.
Dale Levitzke has been appointed as CEO of Sphere Fluidics. He follows CEO and co-founder Dr Frank F. Craig, who announced his retirement after 14 years leading the company.
Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors. Furthermore, using them together with a powerful bioprocess controller like the BioFlo® 320 enables precise cell culture parameter control and seamless process transition to up to 40 L of working volume.
Global contract research organization honored as top outsourcing partner, earning high marks in several categories from Industry Standard Research.
Oslo-based Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance.
Dr Trevor Hawkins, entrepreneur, scientist, and leader with experience in global healthcare companies, has joined the Supervisory Board of Polish molecular diagnostic company Genomtec S.A.
From July 10th to 11th, the multidisciplinary Curious2024 – Future Insight™️ Conference is bringing together some of the world’s brightest scientists, including several Nobel laureates, and the most accomplished innovators to present their work and explore the future of science and technology, solving the challenges of today and enabling the dreams of a better tomorrow.
Leiden-based Amarna Therapeutics welcomed Aurelia Caparrós as its new Chief Business Officer (CBO) in April.
Finnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.
At a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will be driven by data, but also will be personalised. Mark Kotter elaborates here in more detail what is needed to unlock a healthcare of tomorrow.